Dianthus Historical Balance Sheet

DNTH Stock

19.87 1.60 8.76%

Trend analysis of Dianthus Therapeutics balance sheet accounts such as Total Current Liabilities of 10.3 M or Total Stockholder Equity of 370.1 M provides information on Dianthus Therapeutics' total assets, liabilities, and equity, which is the actual value of Dianthus Therapeutics to its prevalent stockholders. By breaking down trends over time using Dianthus Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Dianthus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Dianthus Therapeutics is a good buy for the upcoming year.

Dianthus Therapeutics Inventory

613,800

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

About Dianthus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Dianthus Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Dianthus Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Dianthus Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Dianthus currently owns. An asset can also be divided into two categories, current and non-current.

Dianthus Therapeutics Balance Sheet Chart

As of now, Dianthus Therapeutics' Non Current Assets Total are increasing as compared to previous years. The Dianthus Therapeutics' current Cash And Short Term Investments is estimated to increase to about 289 M, while Other Current Liabilities is projected to decrease to under 7.4 M.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Total Assets

Total assets refers to the total amount of Dianthus Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Dianthus Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Dianthus Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Dianthus Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Dianthus Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Dianthus Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.As of now, Dianthus Therapeutics' Non Current Assets Total are increasing as compared to previous years. The Dianthus Therapeutics' current Cash And Short Term Investments is estimated to increase to about 289 M, while Other Current Liabilities is projected to decrease to under 7.4 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	6.6M	6.5M	13.1M	7.4M
Total Assets	83.1M	179.4M	374.0M	392.7M

Other Current Liab Total Assets

Dianthus Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Non Currrent Assets Other	Other Assets	Short Term Investments	Non Current Liabilities Total	Net Tangible Assets	Inventory	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.83	0.85	0.97	0.37	-0.38	-0.79	0.73	0.39	0.91	0.99	-0.75	0.87	0.98	0.76	0.19	0.99	0.43	0.9	0.8	0.81	-0.05	-0.68	0.66	0.89	0.78
Other Current Liab	0.83		0.99	0.75	0.62	-0.52	-0.85	0.71	0.53	0.61	0.87	-0.81	0.55	0.88	0.72	0.37	0.86	0.68	0.6	0.68	0.47	0.17	-0.53	0.59	0.55	0.65
Total Current Liabilities	0.85	0.99		0.79	0.6	-0.51	-0.87	0.81	0.52	0.65	0.89	-0.79	0.58	0.9	0.74	0.31	0.89	0.63	0.63	0.68	0.51	0.1	-0.53	0.61	0.6	0.67
Total Stockholder Equity	0.97	0.75	0.79		0.36	-0.39	-0.77	0.75	0.39	0.9	0.95	-0.75	0.85	0.96	0.78	-0.05	0.96	0.26	0.9	0.68	0.83	-0.29	-0.55	0.53	0.9	0.69
Property Plant And Equipment Net	0.37	0.62	0.6	0.36		-0.44	-0.81	0.5	0.44	0.12	0.44	-0.47	0.0	0.51	0.42	0.04	0.43	0.44	0.12	0.04	0.07	-0.08	0.12	-0.13	-0.03	-0.09
Net Debt	-0.38	-0.52	-0.51	-0.39	-0.44		0.51	-0.35	-1.0	0.01	-0.5	0.68	0.04	-0.49	-0.33	0.02	-0.49	-0.2	-0.04	-0.33	0.17	0.12	0.34	-0.32	-0.2	-0.18
Retained Earnings	-0.79	-0.85	-0.87	-0.77	-0.81	0.51		-0.78	-0.51	-0.57	-0.84	0.75	-0.48	-0.84	-0.73	-0.14	-0.83	-0.57	-0.55	-0.5	-0.48	0.06	0.32	-0.33	-0.49	-0.41
Accounts Payable	0.73	0.71	0.81	0.75	0.5	-0.35	-0.78		0.35	0.59	0.74	-0.53	0.51	0.75	0.68	-0.06	0.75	0.34	0.56	0.42	0.51	-0.23	-0.29	0.38	0.54	0.49
Cash	0.39	0.53	0.52	0.39	0.44	-1.0	-0.51	0.35		-0.01	0.51	-0.68	-0.03	0.5	0.33	-0.02	0.5	0.21	0.04	0.33	-0.16	-0.11	-0.34	0.33	0.2	0.18
Non Current Assets Total	0.91	0.61	0.65	0.9	0.12	0.01	-0.57	0.59	-0.01		0.83	-0.54	0.99	0.83	0.69	0.1	0.84	0.27	0.98	0.71	0.97	-0.12	-0.57	0.56	0.93	0.77
Cash And Short Term Investments	0.99	0.87	0.89	0.95	0.44	-0.5	-0.84	0.74	0.51	0.83		-0.8	0.79	0.99	0.76	0.21	1.0	0.47	0.83	0.8	0.72	-0.03	-0.68	0.66	0.83	0.75
Net Receivables	-0.75	-0.81	-0.79	-0.75	-0.47	0.68	0.75	-0.53	-0.68	-0.54	-0.8		-0.49	-0.81	-0.84	-0.06	-0.79	-0.56	-0.49	-0.55	-0.38	0.14	0.4	-0.4	-0.58	-0.45
Common Stock Shares Outstanding	0.87	0.55	0.58	0.85	0.0	0.04	-0.48	0.51	-0.03	0.99	0.79	-0.49		0.78	0.65	0.13	0.8	0.24	0.98	0.76	0.95	-0.07	-0.65	0.63	0.95	0.82
Other Current Assets	0.98	0.88	0.9	0.96	0.51	-0.49	-0.84	0.75	0.5	0.83	0.99	-0.81	0.78		0.79	0.15	0.98	0.45	0.83	0.74	0.72	-0.09	-0.6	0.59	0.81	0.7
Other Stockholder Equity	0.76	0.72	0.74	0.78	0.42	-0.33	-0.73	0.68	0.33	0.69	0.76	-0.84	0.65	0.79		-0.03	0.76	0.59	0.61	0.53	0.55	-0.24	-0.32	0.31	0.67	0.45
Total Liab	0.19	0.37	0.31	-0.05	0.04	0.02	-0.14	-0.06	-0.02	0.1	0.21	-0.06	0.13	0.15	-0.03		0.21	0.71	0.09	0.57	0.0	0.97	-0.6	0.56	0.03	0.44
Total Current Assets	0.99	0.86	0.89	0.96	0.43	-0.49	-0.83	0.75	0.5	0.84	1.0	-0.79	0.8	0.98	0.76	0.21		0.46	0.84	0.8	0.73	-0.03	-0.69	0.67	0.84	0.76
Common Stock	0.43	0.68	0.63	0.26	0.44	-0.2	-0.57	0.34	0.21	0.27	0.47	-0.56	0.24	0.45	0.59	0.71	0.46		0.17	0.52	0.1	0.58	-0.38	0.36	0.15	0.34
Non Currrent Assets Other	0.9	0.6	0.63	0.9	0.12	-0.04	-0.55	0.56	0.04	0.98	0.83	-0.49	0.98	0.83	0.61	0.09	0.84	0.17		0.73	0.96	-0.12	-0.63	0.61	0.94	0.8
Other Assets	0.8	0.68	0.68	0.68	0.04	-0.33	-0.5	0.42	0.33	0.71	0.8	-0.55	0.76	0.74	0.53	0.57	0.8	0.52	0.73		0.57	0.39	-0.96	0.93	0.8	0.92
Short Term Investments	0.81	0.47	0.51	0.83	0.07	0.17	-0.48	0.51	-0.16	0.97	0.72	-0.38	0.95	0.72	0.55	0.0	0.73	0.1	0.96	0.57		-0.19	-0.45	0.44	0.86	0.68
Non Current Liabilities Total	-0.05	0.17	0.1	-0.29	-0.08	0.12	0.06	-0.23	-0.11	-0.12	-0.03	0.14	-0.07	-0.09	-0.24	0.97	-0.03	0.58	-0.12	0.39	-0.19		-0.46	0.44	-0.18	0.29
Net Tangible Assets	-0.68	-0.53	-0.53	-0.55	0.12	0.34	0.32	-0.29	-0.34	-0.57	-0.68	0.4	-0.65	-0.6	-0.32	-0.6	-0.69	-0.38	-0.63	-0.96	-0.45	-0.46		-0.96	-0.72	-0.89
Inventory	0.66	0.59	0.61	0.53	-0.13	-0.32	-0.33	0.38	0.33	0.56	0.66	-0.4	0.63	0.59	0.31	0.56	0.67	0.36	0.61	0.93	0.44	0.44	-0.96		0.7	0.95
Net Invested Capital	0.89	0.55	0.6	0.9	-0.03	-0.2	-0.49	0.54	0.2	0.93	0.83	-0.58	0.95	0.81	0.67	0.03	0.84	0.15	0.94	0.8	0.86	-0.18	-0.72	0.7		0.84
Property Plant And Equipment Gross	0.78	0.65	0.67	0.69	-0.09	-0.18	-0.41	0.49	0.18	0.77	0.75	-0.45	0.82	0.7	0.45	0.44	0.76	0.34	0.8	0.92	0.68	0.29	-0.89	0.95	0.84

Click cells to compare fundamentals

Dianthus Therapeutics Account Relationship Matchups

Dianthus Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	161.6M	9.5M	83.1M	179.4M	374.0M	392.7M
Other Current Liab	7.7M	4.0M	6.6M	6.5M	13.1M	7.4M
Total Current Liabilities	11.4M	5.4M	8.2M	9.6M	18.5M	10.3M
Total Stockholder Equity	143.9M	(17.2M)	(44.4M)	168.9M	352.5M	370.1M
Property Plant And Equipment Net	8.3M	33K	956K	800K	1.7M	2.4M
Net Debt	(58.2M)	(7.6M)	(14.6M)	(131.7M)	(21.3M)	(22.4M)
Retained Earnings	(254.4M)	(17.4M)	(45.9M)	(89.4M)	(174.4M)	(165.7M)
Accounts Payable	3.8M	1.4M	1.2M	2.6M	4.6M	2.6M
Cash	58.2M	7.6M	15.4M	132.3M	22.8M	21.7M
Non Current Assets Total	10.1M	63K	1.1M	2.0M	93.1M	97.8M
Cash And Short Term Investments	148.8M	7.6M	75.5M	173.7M	275.2M	289.0M
Common Stock Shares Outstanding	2.7M	3.4M	3.7M	5.2M	34.2M	35.9M
Liabilities And Stockholders Equity	161.6M	9.5M	83.1M	179.4M	374.0M	392.7M
Other Current Assets	2.7M	274K	905K	3.3M	5.7M	5.9M
Other Stockholder Equity	398.3M	498.3M	(116.4M)	258.2M	526.7M	553.1M
Total Liab	17.7M	26.7M	127.5M	10.5M	21.5M	29.6M
Total Current Assets	151.5M	9.4M	82.0M	177.5M	280.9M	294.9M
Accumulated Other Comprehensive Income	(23K)	(30K)	(161K)	47K	106K	111.3K
Common Stock	49K	59K	61K	15K	31K	36.2K
Non Currrent Assets Other	1.0	(1.8M)	61K	1.1M	9.6M	10.1M
Short Term Investments	90.7M	45.3M	60.1M	41.4M	252.4M	265.1M
Non Current Liabilities Total	6.3M	21.3M	119.3M	904K	3.1M	2.9M

Currently Active Assets on Macroaxis

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria
HMY	Harmony Gold Mining
FSM	Fortuna Silver Mines

When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:

How To Invest In Dianthus

Details

Is Dianthus Stock a good investment?

Details

What is Dianthus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.55)

Revenue Per Share

0.187

Quarterly Revenue Growth

1.902

Return On Assets

(0.23)

Return On Equity

(0.33)

The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dianthus Historical Balance Sheet

Dianthus Therapeutics Inventory

613,800

About Dianthus Balance Sheet Analysis

Dianthus Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Dianthus Therapeutics balance sheet Correlations

Dianthus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Dianthus Therapeutics balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Common Stock Shares Outstanding	+ 0.99	Non Current Assets Total
Other Current Assets	+ 0.99	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Inventory	- 0.96	Net Tangible Assets
Net Tangible Assets	- 0.96	Other Assets
Property Plant And Equipment Gross	- 0.89	Net Tangible Assets
Retained Earnings	- 0.87	Total Current Liabilities
Retained Earnings	- 0.85	Other Current Liab